Quantum Computing Inc. Announces Agreement to Acquire QPhoton Delivering First Commercially Available, Ready-to-Run Full-Stack Quantum Solution
May 24, 2022
Ensysce Biosciences Announces Closing of Merger
June 30, 2021
Town of West New York Offering New Coronavirus and Antibody Testing
June 23, 2020
Hoboken Begins Rapid Antibody Testing
Hoboken to Launch COVID-19 Antibody Testing Pilot for First Responders, Frontline Workers
May 7, 2020
Power Analytics Global & Inspire Health Alliance Announce New COVID-19 Antibody Testing and Real-Time Data Certification Platform​
April 10, 2020
Power Analytics Global Announces New COVID-19 Impact Data Simulation Product
March 30, 2020
Power Analytics Global & Molecula Announce Strategic Partnership
March 5, 2020
WaveTech Global Announces Filing of Name Change to PAC Global, Inc.
November 12, 2019
Federal Aviation Administration Awards Power Analytics New 5-Year Software License Agreement
October 28, 2019
Power Analytics Expands Global Patent Portfolio and the new release of software version 6.2 for DesignBase   
October 21, 2019
WaveTech Global Acquires Power Analytics
April 29, 2019
WaveTech Highlighted in News Special on TV2
February 25, 2018
NuLife Announces Planned Merger with Ensysce Biosciences
October 31, 2017
Prism Technologies Group Enters into Asset Purchase Agreement with Amorphous Technologies International
October 20, 2017
Precipio and Transgenomic Complete Merger
June 30, 2017
Precipio and Transgenomic Announce Experts from Yale and Harvard Joining New Scientific Advisory Board
June 16, 2017
European Patent Office Confirms Grant of New ICE COLD-PCR Patent Exclusively Licensed to Transgenomic
June 13, 2017
Ensysce Attending NIH Conference: Cutting Edge Science Meeting Series to End the Opioid Crisis: Development of Safe, Effective, Non-Addictive Pain Treatments
June 12, 2017
Transgenomic Stockholders and Precipio Diagnostics Members Approve Merger
June 6, 2017
Precipio Renews Yale Agreement
April 21, 2017
Transgenomic Closes Bridge Financing
April 13, 2017
Ensysce Biosciences Inc. Publishes Manuscript Describing the in Vitro Abuse Deterrence of Oxycodone Prodrug, PF614
April 3, 2017
Ensysce Biosciences Inc. Initiates Phase 1 Clinical Trial to Study PF614, BIO-MD™ Prodrug of Oxycodone
December 1, 2016
Transgenomic and Precipio Diagnostics Announce Planned Merger
October 13, 2016
Ensysce Biosciences Inc. and Signature Therapeutics Inc. Merger
December 31, 2015
2022 BV Advisory Partners, LLC